Fluxa

Fluxa, Inc. operates as a specialized software provider for the life sciences sector, focusing on accelerating the development and manufacturing of new therapies. Founded in 2017 by John Miller, Sudheesh Narayanan, and Suraj Pai, the company established its headquarters in Glendale, California. The firm was developed to address the increasing pressure on pharmaceutical operations for faster speed-to-market, particularly highlighted since the COVID-19 pandemic.

The company's core offering is the Process & Knowledge Management (PKM™) software, a web-based platform also known as Scale-Up. This tool is designed to manage product and process specifications throughout the entire drug development lifecycle, from initial research to full-scale manufacturing. Fluxa serves drug development and manufacturing organizations, including Contract Development and Manufacturing Organizations (CDMOs), by providing a collaborative environment for teams across different global sites and functions. Revenue is generated through the licensing of its PKM™ software. The software facilitates the translation and transfer of scientific processes and workflows into the operational technology language used in manufacturing facilities.

The PKM™ platform features a visual, drag-and-drop interface for creating process specifications that conform to ISA-88 standards. It includes a parameter calculation engine to manage process parameters without relying on spreadsheets and predictive algorithms for real-time facility fit analysis. A key benefit is the platform's ability to digitize the tech transfer process, which significantly reduces the time and manual effort required to move a drug from development to production. The system is designed for regulated environments, being CFR-11 compliant with features like full audit logging, electronic signatures, and version management. It can also integrate with other enterprise systems such as ERP, LIMS, and MES.

In February 2021, Emerson, a global technology and engineering company, made an initial equity investment in Fluxa. This partnership aimed to couple Fluxa's PKM software with Emerson's established DeltaV™ control system and Syncade™ manufacturing execution systems. Subsequently, Emerson fully acquired Fluxa in June 2022, integrating the company into its Automation Solutions business to offer a more comprehensive solution for the life sciences market. This acquisition enables a more streamlined approach to digitizing the drug development pipeline, aiming to enhance speed, flexibility, and operational integrity for biopharmaceutical companies.

Keywords: process knowledge management, PKM software, life sciences automation, drug development software, tech transfer automation, pharmaceutical manufacturing, biopharmaceutical, recipe management, process specification, DeltaV integration, speed to market, clinical manufacturing, ISA-88, CFR-11 compliance, process development, technology transfer, drug lifecycle management, CDMO, scale-up, Emerson